- Home
- GECC vs COEP Comparison
GECC vs COEP Comparison
Compare GECC & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GECC | COEP |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.8M | 100.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GECC | COEP |
|---|---|---|
| Price | $5.86 | $11.45 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.75 | N/A |
| AVG Volume (30 Days) | ★ 75.9K | 35.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 25.50% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $32.31 | N/A |
| Revenue Next Year | $1.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.64 | $6.32 |
| 52 Week High | $11.45 | $21.41 |
Technical Indicators
Market Signals| Indicator | GECC | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 28.18 | 44.99 |
| Support Level | N/A | $11.76 |
| Resistance Level | $7.16 | $12.71 |
| Average True Range (ATR) | 0.28 | 0.67 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 15.67 | 51.18 |
Price Performance
Historical ComparisonAbout GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.